drugset / Trial / NCT00313976

Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)

NCT00313976

Phase 3 Withdrawn Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate if the higher dose can give greater efficacy without negative impact on the adverse event profile for patients with early secondary progressive Multiple Sclerosis (SPMS).

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon beta-1b Protein / enzyme biologic 250 ug Subcutaneous
Subject Interferon beta-1b Protein / enzyme biologic 500 ug Subcutaneous

Indications